Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 22, 2022 at 04:47 am EDT
Share
Hvsen Biotechnology Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 205.67 million compared to CNY 313.5 million a year ago. Revenue was CNY 205.67 million compared to CNY 313.5 million a year ago. Net income was CNY 2.02 million compared to CNY 63.46 million a year ago. Basic earnings per share from continuing operations was CNY 0.01 compared to CNY 0.38 a year ago. Diluted earnings per share from continuing operations was CNY 0.01 compared to CNY 0.38 a year ago.
Wuhan Hvsen Biotechnology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of veterinary drugs, feed and additives. The Companyâs main products include veterinary active pharmaceutical ingredients, veterinary chemical preparations, veterinary traditional Chinese medicine preparations, feed and additives and environmental improvers, such as tyvanicin tartrate, florfenicol powder, banqing granules and piglet composites pre-mixed feed, etc. The Company mainly conducts its businesses in the China market.